Tekin, TubaCicek, BetulKonyaligil, Nurefsan2024-10-262024-10-2620191308-87341308-8742https://doi.org/10.5152/eurasianjmed.2019.18420https://search.trdizin.gov.tr/tr/yayin/detay/333853https://hdl.handle.net/20.500.12418/27492Metabolic syndrome is associated with a group of conditions abdominal obesity, high triglyceride levels, reduction in low-density lipoprotein, increased blood pressure, and increased fasting blood glucose. Hence, it poses a risk for type 2 diabetes and cardiovascular diseases. The prevalence of metabolic syndrome increases with age. Nesfatin-1. which affects different systems, has recently been discovered as a regulatory peptide molecule. With the discovery of nesfatin-1, it has been reported to inhibit the intake of nutrients and have significant regulatory effects on energy metabolism. As nesfatin-1 is present in both central and peripheral tissues, it is thought to have many functions. In addition to its suppressive effect on food intake, nesfatin-1 has also been reported to have an effect on the blood glucose level for regulating cardiac functions and affecting obesity by providing weight loss. Considering the effects of nesfatin-1, it may be associated with metabolic syndrome.en10.5152/eurasianjmed.2019.18420info:eu-repo/semantics/openAccessMetabolic syndromeNesfatin-1obesitypeptideReview Article513284280316927102-s2.0-85075712448Q3333853WOS:000491164700017N/A